Kedia purchased the shares via his investment company Kedia Securities Private Ltd at a 2.8% discount from the Monday closing price of Rs 144.05 per share.
Listed on November 18, 2025, Mahamaya Lifesciences shares hit their all-time high of Rs 161.70 on the BSE, today.
The stock also witnessed another block deal where, Almondz Global Securities Limited sold 1.51 lakh shares at a price of Rs 143.64 per share.
Mahamaya Lifesciences is a manufacturer and exporter of pesticide formulations and crop protection products which is listed on the BSE SME platform.
The stock had a lackluster listing at Rs 116 a share against the issue price of Rs 114. But the stock has extended its lead since making its market debut. It is now up 42% over the IPO price.Also Read: Ola Electric bulk deal: Promoter Bhavish Aggarwal sells 2.6 crore shares worth Rs 92 croreThe Rs 70.44 crore IPO consisted of a fresh issue worth Rs 64.28 crore and an offer for sale of Rs 6.16 crore.
The IPO was subscribed 1.63 times overall, led by strong NII participation at 3.63 times, while the retail category ended at 1.02 times—just above full subscription. QIBs bid 1.19 times, reflecting a measured institutional stance. The issue’s high minimum investment size of Rs 2,73,600 for retail investors also meant limited participation from small applicants.
Mahamaya Lifesciences manufactures pesticide formulations, technical-grade molecules and branded agri-inputs. It supplies bulk products to domestic agrochemical companies and several multinational firms.
The company also has a global footprint, with product registrations and sales in countries including Egypt, Ethiopia, Jordan, the UAE and Turkey. Its product portfolio spans key formulations such as Acetamiprid, Emamectin Benzoate, Imidacloprid, Paraquat Dichloride and multiple branded plant-health products.
The company posted strong growth in FY25, with revenue rising 64% to Rs 267.17 crore, while PAT grew 148% to Rs 12.94 crore. EBITDA increased to Rs 24.64 crore, and net worth nearly doubled to Rs 49.42 crore.
IPO proceeds will be used for equipment purchases, setting up a new technical manufacturing plant, warehouse construction, working-capital needs, and general corporate purposes.
Also Read: Usha Martin block deal: Promoter entity sells stake worth Rs 99 crore. Morgan Stanley among buyers
(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)
